Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Change in Accured Expenses (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Change in Accured Expenses for 13 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 4.3% year-over-year to $5.8 million, compared with a TTM value of $6.0 million through Dec 2025, down 71.26%, and an annual FY2025 reading of $6.0 million, down 71.26% over the prior year.
  • Change in Accured Expenses was $5.8 million for Q4 2025 at Tandem Diabetes Care, down from $12.8 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $15.8 million in Q3 2024 and bottomed at -$23.8 million in Q3 2022.
  • Average Change in Accured Expenses over 5 years is $1.2 million, with a median of $1.1 million recorded in 2024.
  • The sharpest move saw Change in Accured Expenses crashed 2066.46% in 2021, then skyrocketed 1048.34% in 2022.
  • Year by year, Change in Accured Expenses stood at -$6.2 million in 2021, then tumbled by 49.4% to -$9.3 million in 2022, then skyrocketed by 204.92% to $9.7 million in 2023, then plummeted by 42.93% to $5.6 million in 2024, then rose by 4.3% to $5.8 million in 2025.
  • Business Quant data shows Change in Accured Expenses for TNDM at $5.8 million in Q4 2025, $12.8 million in Q3 2025, and $1.1 million in Q2 2025.